Physician profile
Stephen V Scoper
NPI 1871592352
$87,578.35
in general payments reported to CMS, 2019-2025
27 companies · $771 in 2025
The $771 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $21K · 2021: $21K · 2022: $4,073 · 2023: $13K · 2024: $336 · 2025: $771.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $8,225 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,450 · Food and Beverage: $1,727 · Travel and Lodging: $1,657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $8,225.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,450.00 |
| Food and Beverage | $1,726.60 |
| Travel and Lodging | $1,656.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $71,264.62 | 2019-2025 | Argos, Clareon, Viscoat |
| Alcon Research LLC | $14,148.69 | 2020 | |
| Allergan, INC. | $346.50 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $241.14 | 2025 | Xdemvy |
| Amgen INC. | $163.74 | 2024-2025 | Tepezza |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $140.97 | 2019 | |
| Lensar, INC. | $130.45 | 2019 | |
| Mallinckrodt Hospital Products INC. | $127.71 | 2020-2024 | Acthar |
| Oyster Point Pharma, INC. | $124.93 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $123.07 | 2022-2023 | Tepezza, Uplizna |
| Carl Zeiss Meditec, INC. | $121.12 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $111.78 | 2024 | Envista Envy |
| Abbvie INC. | $98.63 | 2022 | |
| Omeros Corporation | $71.37 | 2020 | |
| Rayner Intraocular Lenses Limited | $62.73 | 2024-2025 | Rayner Cataract Set 1, Rayone Emv, Rayone Aspheric |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $59.56 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $45.03 | 2022-2025 | Tecnis Simplicity |
| Mallinckrodt Enterprises LLC | $35.93 | 2019 | |
| Apellis Pharmaceuticals, INC. | $26.66 | 2025 | Syfovre |
| Biotissue Holdings INC. | $23.08 | 2023 | |
| Ani Pharmaceuticals, INC. | $22.24 | 2025 | Purified Cortrophin Gel |
| Dompe US, INC. | $21.63 | 2025 | Oxervate |
| Ocular Therapeutix, INC. | $20.19 | 2023 | Dextenza |
| Sun Pharmaceutical Industries INC. | $16.79 | 2023 | Cequa |
| Merz North America, INC. | $15.06 | 2019 | |
| Harrow Eye, LLC | $14.73 | 2024 | Vevye |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Scoper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.